胡锦成,鲍剑峰

Pott截瘫是脊柱结核的严重并发症之一，其特征为下肢运动和感觉功能障碍。近年来，一些研究开始关注Pott截瘫患者血清中神经丝轻链蛋白（NFL）的表达水平及其与神经症状的关联性。本综述旨在总结和分析已发表的相关研究，以增进对NFL在Pott截瘫中的潜在作用的理解。通过文献检索，我们找到了多篇研究报告，其中对Pott截瘫患者血清中NFL表达水平进行了评估，并与神经症状进行了相关性分析。结果显示，Pott截瘫患者血清中NFL表达水平明显升高。这一升高可能与脊柱结核骨质破坏造成的神经损伤有关。此外，高NFL水平与疾病的严重程度和脊柱畸形的发展有关。与神经症状的相关性研究表明，高NFL水平与下肢运动和感觉障碍的存在呈正相关。这提示NFL可能作为一个潜在的生物标记物，用于评估Pott截瘫的严重程度和预测病情的进展。另外，一些研究还发现NFL与膀胱和直肠功能障碍之间存在相关性，进一步支持了NFL在Pott截瘫中的潜在作用。尽管这些研究结果表明血清中NFL可能在Pott截瘫的评估和监测中具有潜在的临床应用价值，但还需要更多的研究来验证这些发现，并进一步探索NFL在Pott截瘫患者中的具体作用机制。

神经丝轻链蛋白；脊柱结核；Pott截瘫；神经症状；生物标志物

[1] GAETANI L,BLENNOW K,CALABRESI P,et al.Neurofilament light chain as a biomarker in neurological disorders[J].Journal of Neurology,Neurosurgery&Psychiatry,2019,90(8):870-81. [2] THEBAULT S,BOOTH R A,FREEDMAN M S.Blood neurofilament light chain:the neurologist’stroponin?[J].Biomedicines,2020,8(11):523. [3] LADANG A,KOVACS S,LENGELéL,et al.Neurofilament light chain concentration in an aging population[J].Aging Clinical and Experimental Research,2022,34(2):331-9. [4] KHALIL M,TEUNISSEN C E,OTTO M,et al.Neurofilaments as biomarkers in neurological disorders[J].Nature Reviews Neurology, 2018,14(10):577-89. [5] KöLLIKER FRERS R A,OTERO-LOSADA M,KOBIEC T,et al.Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis[J].Frontiers in Immunology,2022,13:912005. [6] BALASTIK M,FERRAGUTI F,PIRES-DA SILVA A,et al.Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration[J].Proceedings of the National Academy of Sciences,2008,105(33):12016-21. [7] NOVAKOVA L,ZETTERBERG H,SUNDSTRöM P,et al.Monitoring disease activity in multiple sclerosis using serum neurofilament light protein[J].Neurology,2017,89(22):2230-7. [8] KUHLE J,BARRO C,ANDREASSON U,et al.Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples:ELISA,electrochemiluminescence immunoassay and Simoa[J].Clinical Chemistry and Laboratory Medicine (CCLM),2016,54(10):1655-61. [9] CLAIRE A L,JOHN C,NICOLAS R B,et al.Development of a targeted proteomic assay for the quantitation of neurofilament light in cerebrospinal fluid:Correlation with Simoa‐based quantitation across neurodegenerative diseases and centres[J].2023,19. [10] ARSLAN B,ZETTERBERG H.Neurofilament light chain as neuronal injury marker–what is needed to facilitate implementation in clinical laboratory practice?[J].Clinical Chemistry and Laboratory Medicine(CCLM),2023,61(7):1140-9. [11] ALIREZAEI Z,POURHANIFEH M H,BORRAN S,et al.Neurofilament light chain as a biomarker,and correlation with magnetic resonance imaging in diagnosis of CNS-related disorders[J].Molecular neurobiology,2020,57:469-91. [12] CLAIRE A L,JOHN B C,TATIANA A G,et al.Cerebrospinal fluid neurofilament light chain profiling and quantitation in neurological diseases[J].Brain communications,2024. [13] TAKUMI N,TAKESHI K,YOSHIO I,et al.High levels of plasma neurofilament light chain correlated with brainstem and peripheral nerve damage[J].Journal of the Neurological Sciences,2024,463:123137-. [14] AHMED N,SHAHIDUL ISLAM KHAN M,KAMRUL AHSAN M.Pott’s Paraplegia[M].Paraplegia-New Insights.IntechOpen.2023. [15] RIDHAM R D,JASSAL Y D,SATODIYA M D.Pott's Spine manifesting as paraplegia in pregnancy and its management:A case report[J].INDIAN JOURNAL OF APPLIED RESEARCH,2024:40-1. [16] SARKAR R,SARKAR S,PRAMANIK A,et al.Pott’s paraplegia-satisfactory outcome in spite of poor prognostic factors,treated by a novel surgical technique of posterior spinal stabilization and anterolateral decompression with bone graft fusion:a case report[J].Int J Res Med Sci,2024,12(6):2137-42.

点击下载PDF